Bayer Pharma Aktiengesellschaft

Tmem16a Limited

Ono Pharmaceutical Co., Ltd.

Evotec Ag

Christopher Charles Stimson

Adam James Davenport

Andrea Rotgeri

Jens Nagel

Juergen Klar

Thomas Dyrks

Edward Walker

Jürgen Klar

Alexandra Rausch

Nicole Schmidt

Clive Mccarthy

Stefan Baeurle

Jonathan David Hargrave

Duncan Alexander Hay

Thomas Beauregard Schofield

Stephen Collingwood

Peter Neville Ingram

Chun Yan Ma

Matthew Raymond Smith

Ina Groeticke

Sarah Ellam

Craig Stephen Buxton

Matthew Habgood

Spencer Charles Robert Napier

Abdul Kadar Shaikh

Masashi Kato

Tetsuji Saito

Kentaro Yashiro

Daisuke Wakamatsu

Ina Gröticke

Stefan Bäurle

David James Hallett

Takuya Okada

Spencer Napier

Compounds of general formula (I): wherein R, R, R, R, R, RX, X, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.

Compounds

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseases a sole agent or in combination with other active ingredients.

Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.

Carboxylic acid aromatic amides

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.

Compounds of general formula (I): wherein R, R, R, R, R, R* X, X, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions. 

An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like). 

KCNQ2-5 channel activator

The invention relates to compounds of formula (I), wherein R, R, m, n and Xto Xhave the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament. 

Azetidines as histamine H3 receptor antagonists

Growing community of inventors

Oxford, United Kingdom

Christopher Charles Stimson